JP6506172B2 - 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 - Google Patents
黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 Download PDFInfo
- Publication number
- JP6506172B2 JP6506172B2 JP2015540852A JP2015540852A JP6506172B2 JP 6506172 B2 JP6506172 B2 JP 6506172B2 JP 2015540852 A JP2015540852 A JP 2015540852A JP 2015540852 A JP2015540852 A JP 2015540852A JP 6506172 B2 JP6506172 B2 JP 6506172B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- nos
- aureus
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019063358A JP6926138B2 (ja) | 2012-11-06 | 2019-03-28 | 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723128P | 2012-11-06 | 2012-11-06 | |
| US61/723,128 | 2012-11-06 | ||
| PCT/US2013/068385 WO2014074470A1 (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019063358A Division JP6926138B2 (ja) | 2012-11-06 | 2019-03-28 | 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536951A JP2015536951A (ja) | 2015-12-24 |
| JP2015536951A5 JP2015536951A5 (enExample) | 2016-12-22 |
| JP6506172B2 true JP6506172B2 (ja) | 2019-04-24 |
Family
ID=50685101
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540852A Active JP6506172B2 (ja) | 2012-11-06 | 2013-11-05 | 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 |
| JP2019063358A Active JP6926138B2 (ja) | 2012-11-06 | 2019-03-28 | 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019063358A Active JP6926138B2 (ja) | 2012-11-06 | 2019-03-28 | 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9845348B2 (enExample) |
| EP (1) | EP2928490B1 (enExample) |
| JP (2) | JP6506172B2 (enExample) |
| KR (3) | KR20150092738A (enExample) |
| CN (2) | CN112316135A (enExample) |
| AU (2) | AU2013341421A1 (enExample) |
| BR (1) | BR112015010126B1 (enExample) |
| CA (1) | CA2890385C (enExample) |
| ES (1) | ES2912267T3 (enExample) |
| MX (1) | MX367082B (enExample) |
| RU (1) | RU2661406C2 (enExample) |
| SG (2) | SG11201503231YA (enExample) |
| WO (1) | WO2014074470A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2838211C (en) | 2011-06-10 | 2023-08-01 | Medimmmune Limited | Anti-pseudomonas psl binding molecules and uses thereof |
| HUE050985T2 (hu) | 2011-11-07 | 2021-01-28 | Medimmune Ltd | Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák |
| KR20150092738A (ko) * | 2012-11-06 | 2015-08-13 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| CN104968797B (zh) * | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| EP3864040A1 (en) | 2018-10-09 | 2021-08-18 | Medimmune, LLC | Antibodies directed against staphylococcus aureus leukotoxins |
| WO2020076789A2 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| TW202100549A (zh) | 2019-03-13 | 2021-01-01 | 美商麥迪紐有限責任公司 | 降低金黃色葡萄球菌在定殖的患者中之感染 |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2719397A1 (en) * | 2006-06-12 | 2014-04-16 | GlaxoSmithKline Biologicals SA | Use of alpha-toxin for treating and preventing staphylococcus infections |
| AU2008292897B2 (en) | 2007-08-31 | 2015-01-22 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| EP2453881A2 (en) * | 2009-07-16 | 2012-05-23 | Georgia Health Sciences University Research Institute, Inc. | Porous-wall hollow glass microspheres as carriers for biomolecules |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| SG10201913690SA (en) * | 2011-02-08 | 2020-03-30 | Medimmune Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| CA2825770A1 (en) * | 2011-02-08 | 2012-08-16 | Integrated Biotherapeutics, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| KR20150092738A (ko) * | 2012-11-06 | 2015-08-13 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
| CN104968797B (zh) | 2012-11-06 | 2018-11-30 | 米迪缪尼有限公司 | 金黄色葡萄球菌表面决定簇的抗体 |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| WO2017075188A2 (en) | 2015-10-30 | 2017-05-04 | Medimmune, Llc | Methods of using anti-alpha toxin antibody |
-
2013
- 2013-11-05 KR KR1020157011460A patent/KR20150092738A/ko not_active Ceased
- 2013-11-05 ES ES13853844T patent/ES2912267T3/es active Active
- 2013-11-05 CN CN202011217117.7A patent/CN112316135A/zh active Pending
- 2013-11-05 CN CN201380057604.3A patent/CN104780934A/zh active Pending
- 2013-11-05 EP EP13853844.2A patent/EP2928490B1/en active Active
- 2013-11-05 WO PCT/US2013/068385 patent/WO2014074470A1/en not_active Ceased
- 2013-11-05 US US14/440,749 patent/US9845348B2/en active Active
- 2013-11-05 RU RU2015121617A patent/RU2661406C2/ru active
- 2013-11-05 SG SG11201503231YA patent/SG11201503231YA/en unknown
- 2013-11-05 BR BR112015010126-7A patent/BR112015010126B1/pt active IP Right Grant
- 2013-11-05 JP JP2015540852A patent/JP6506172B2/ja active Active
- 2013-11-05 AU AU2013341421A patent/AU2013341421A1/en not_active Abandoned
- 2013-11-05 CA CA2890385A patent/CA2890385C/en active Active
- 2013-11-05 SG SG10201703677VA patent/SG10201703677VA/en unknown
- 2013-11-05 KR KR1020207024078A patent/KR102272744B1/ko active Active
- 2013-11-05 MX MX2015005481A patent/MX367082B/es active IP Right Grant
- 2013-11-05 KR KR1020217020104A patent/KR20210083389A/ko not_active Ceased
-
2017
- 2017-12-18 US US15/845,701 patent/US10457724B2/en active Active
-
2018
- 2018-09-28 AU AU2018236849A patent/AU2018236849B2/en active Active
-
2019
- 2019-03-28 JP JP2019063358A patent/JP6926138B2/ja active Active
- 2019-10-11 US US16/599,595 patent/US10759849B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6506172B2 (ja) | 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 | |
| KR102288394B1 (ko) | 스타필로코커스 아우레우스 표면 결정인자에 대한 항체 | |
| AU2015276938B2 (en) | Treatment of polybacterials infections | |
| US20150044168A1 (en) | Treatment of Multiple Sclerosis With Anti-CD19 Antibody | |
| CA3121934A1 (en) | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant | |
| HK1215173B (en) | Methods of treating s. aureus-associated diseases | |
| RU2804815C2 (ru) | Комбинации антител к staphylococcus aureus | |
| TW202511292A (zh) | 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白 | |
| HK40025295A (en) | Antibodies to s. aureus surface determinants | |
| HK1215452B (zh) | 金黃色葡萄球菌表面決定簇的抗體 | |
| HK1236126A1 (en) | Treatment of polybacterials infections | |
| HK1236126B (en) | Treatment of polybacterials infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161104 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171024 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180529 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190204 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190328 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6506172 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |